Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics, Inc. (CMPX) Healthcare & Pipeline Overview

Compass Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in antibody-based therapeutics for oncology, focusing on bispecific and monoclonal antibodies like CTX-009 and CTX-471. The company aims to address unmet needs in cancer treatment by targeting critical signaling pathways involved in angiogenesis and tumor vascularization.

What Is the Investment Thesis for CMPX?

Compass Therapeutics presents a notable research candidate in the oncology-focused biopharmaceutical sector. The company's pipeline of antibody-based therapeutics, including CTX-009, CTX-471, and CTX-8371, targets critical pathways in angiogenesis, tumor immunity, and checkpoint blockade. A key value driver is the potential clinical success of these candidates, particularly CTX-009, which could address significant unmet needs in cancer treatment. Upcoming clinical trial results for CTX-009 and CTX-471 will serve as major catalysts. The company's market capitalization of $315.98M reflects both the potential and the risks inherent in clinical-stage drug development. However, potential setbacks in clinical trials or regulatory hurdles pose significant risks. The company's beta of 1.30 indicates higher volatility compared to the overall market.

Based on FMP financials and quantitative analysis

CMPX Key Highlights

• Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology.
• The company's lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4/Notch and VEGF-A signaling pathways.
• CTX-471, an IgG4 monoclonal antibody, acts as an agonist of CD137 to enhance anti-tumor immune responses.
• CTX-8371 is a bispecific inhibitor targeting PD-1 and PD-L1, aiming to improve checkpoint blockade immunotherapy.
• The company has a market capitalization of $315.98M.

Who Are CMPX's Competitors?

CMPX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CMPX's Key Strengths?

• Novel antibody-based therapeutics pipeline.
• Focus on unmet needs in cancer treatment.
• Proprietary antibody discovery platform.
• Experienced management team.

What Are CMPX's Weaknesses?

• Clinical-stage company with no approved products.
• Reliance on clinical trial outcomes and regulatory approvals.
• Limited financial resources compared to larger pharmaceutical companies.
• High R&D costs and long development timelines.

What Could Drive CMPX Stock Higher?

• Clinical trial results for CTX-009 in solid tumors.
• Clinical trial results for CTX-471 in immuno-oncology.
• Advancement of CTX-8371 into clinical development.
• Potential strategic partnerships and licensing agreements.

What Are the Key Risks for CMPX?

• Negative return on equity (-39.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for CTX-009, CTX-471, or CTX-8371.
• Regulatory hurdles and rejection of product candidates by the FDA.
• Competition from larger pharmaceutical companies with more resources.
• Patent challenges and intellectual property disputes.
• Dependence on securing additional funding to support R&D activities.

What Are the Growth Opportunities for CMPX?

• Expansion of CTX-009 Clinical Trials: Compass Therapeutics has the opportunity to expand the clinical trials for CTX-009 into additional cancer types beyond those currently being investigated. Given CTX-009's mechanism of action in targeting angiogenesis and tumor vascularization, it could potentially be effective in a range of solid tumors. The global market for solid tumor therapies is substantial, estimated to reach hundreds of billions of dollars by 2028, offering significant revenue potential if CTX-009 demonstrates efficacy and receives regulatory approval. This expansion is contingent on positive early-stage trial results and securing additional funding.
• Advancement of CTX-471 in Immuno-Oncology: CTX-471, as an agonist of CD137, holds promise in enhancing anti-tumor immune responses. Compass Therapeutics can explore combination therapies involving CTX-471 with other immunotherapies, such as checkpoint inhibitors, to improve treatment outcomes. The immuno-oncology market is rapidly growing, driven by the success of checkpoint inhibitors, and is projected to reach significant market size by 2027. Successful clinical trials demonstrating synergistic effects with existing immunotherapies could drive significant value for CTX-471.
• Development of CTX-8371 for Checkpoint Blockade: The development of CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1, presents an opportunity to improve the efficacy of checkpoint blockade immunotherapy. Compass Therapeutics can focus on specific patient populations or tumor types where existing checkpoint inhibitors have limited efficacy. The market for checkpoint inhibitors is substantial, but resistance and limited response rates remain challenges. A successful CTX-8371 could capture a share of this market by addressing these limitations.
• Strategic Partnerships and Licensing Agreements: Compass Therapeutics can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide access to additional funding, expertise, and resources. The biotechnology industry is characterized by frequent collaborations between smaller biotech firms and larger pharmaceutical companies, offering opportunities for Compass Therapeutics to leverage its assets and expertise.
• Expansion into New Therapeutic Areas: While currently focused on oncology, Compass Therapeutics can leverage its antibody discovery platform to expand into new therapeutic areas, such as autoimmune diseases or inflammatory conditions. The market for antibody-based therapeutics extends beyond oncology, with significant opportunities in other disease areas. This expansion would require additional investment in research and development, but could diversify the company's pipeline and reduce its reliance on oncology.

What Opportunities Does CMPX Have?

• Expansion of clinical trials into new cancer types.
• Strategic partnerships and licensing agreements.
• Advancement of CTX-471 and CTX-8371 in immuno-oncology.
• Expansion into new therapeutic areas beyond oncology.

What Threats Does CMPX Face?

• Clinical trial failures or delays.
• Regulatory hurdles and rejection of product candidates.
• Competition from larger pharmaceutical companies.
• Patent challenges and intellectual property disputes.

What Are CMPX's Competitive Advantages?

• Proprietary antibody discovery platform.
• Pipeline of novel antibody-based therapeutics targeting unmet needs in cancer treatment.
• Intellectual property protection for their product candidates.
• Clinical data supporting the safety and efficacy of their therapies.

What Does CMPX Do?

Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company dedicated to developing innovative antibody-based therapeutics for treating various human diseases. The company's core strategy revolves around leveraging its proprietary antibody discovery platform to create novel therapies that address unmet needs in cancer treatment. Compass Therapeutics' lead product candidates include CTX-009, an investigational bispecific antibody designed to simultaneously block Delta-like ligand 4/Notch and vascular endothelial growth factor A (VEGF-A) signaling pathways, both of which are crucial for angiogenesis and tumor vascularization. CTX-009 is currently in clinical development. Another key asset is CTX-471, an IgG4 monoclonal antibody that acts as an agonist of CD137, a costimulatory receptor on immune cells, aiming to enhance anti-tumor immune responses. Additionally, the company is developing CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1, aiming to improve the efficacy of checkpoint blockade immunotherapy. Compass Therapeutics operates with a team of 35 employees.

What Products and Services Does CMPX Offer?

• Develop antibody-based therapeutics for cancer treatment.
• Focus on bispecific antibodies and monoclonal antibodies.
• Target key signaling pathways in angiogenesis and tumor immunity.
• Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
• Seek regulatory approval for their therapies from agencies like the FDA.
• Potentially commercialize approved therapies or partner with larger pharmaceutical companies.

How Does CMPX Make Money?

• Develop proprietary antibody-based therapeutics.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through milestone payments and royalties from partnered programs.

What Industry Does CMPX Operate In?

The biotechnology industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. Oncology remains a significant area of focus, driven by the increasing prevalence of cancer and the demand for more effective treatments. Compass Therapeutics operates within this landscape, competing with both large pharmaceutical companies and smaller biotech firms developing novel cancer therapies. The market for antibody-based therapeutics is substantial, with global oncology therapeutics market projected to reach hundreds of billions of dollars by 2026. Success depends on clinical trial outcomes, regulatory approvals, and commercialization strategies.

Who Are CMPX's Key Customers?

• Patients with cancer who may benefit from their therapies.
• Healthcare providers who prescribe and administer cancer treatments.
• Pharmaceutical companies that may partner with Compass Therapeutics for development and commercialization.

How Compass Therapeutics, Inc. Is Valued

Compass Therapeutics, Inc. carries a market capitalization of $315.98M, placing it in the small-cap category. Relative to its peer group, CMPX's quantitative score of 45/100 is below the peer average of 84/100.

ROE -40%Key Financial Metrics

Return on equity for Compass Therapeutics, Inc. stands at -39.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Compass Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.99 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Compass Therapeutics, Inc. revenue of about $-2.2M for fiscal 2026, with EPS near $-0.44. The estimate reflects 9 contributing analysts.

CMPX Financials

CMPX Latest News

No recent news available for CMPX.

CMPX Analyst Consensus

CMPX MoonshotScore

Common Questions About CMPX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources